Sino Biopharmaceutical (HKSE:01177) Total Tax Payable : HK$585 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Total Tax Payable?

Sino Biopharmaceutical's Total Tax Payable for the quarter that ended in Dec. 2024 was HK$585 Mil.

Sino Biopharmaceutical's quarterly Total Tax Payable declined from Dec. 2023 (HK$564 Mil) to Jun. 2024 (HK$438 Mil) but then increased from Jun. 2024 (HK$438 Mil) to Dec. 2024 (HK$585 Mil).

Sino Biopharmaceutical's annual Total Tax Payable increased from Dec. 2022 (HK$370 Mil) to Dec. 2023 (HK$564 Mil) and increased from Dec. 2023 (HK$564 Mil) to Dec. 2024 (HK$585 Mil).

Sino Biopharmaceutical Total Tax Payable Historical Data

The historical data trend for Sino Biopharmaceutical's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Total Tax Payable Chart

Sino Biopharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Tax Payable

Get a 7-Day Free Trial

315.49

420.79

369.51

564.40

584.84

Sino Biopharmaceutical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Tax Payable	Get a 7-Day Free Trial															369.51	194.78	564.40	438.04	584.84

Sino Biopharmaceutical Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Sino Biopharmaceutical Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Executives

Tse Ping	2101 Beneficial owner
Tse Eric S Y	2101 Beneficial owner
Cheng Cheung Ling	2101 Beneficial owner
True Merit Global Limited	2101 Beneficial owner
Tse Theresa Y Y	2101 Beneficial owner
Thousand Eagles Limited	2101 Beneficial owner
France Investment (china 1) Group Limited	2101 Beneficial owner
Remarkable Industries Limited	2101 Beneficial owner
Validated Profits Limited	2101 Beneficial owner

Sino Biopharmaceutical Headlines

No Headlines